drugset / Trial / NCT03196830

CAR-T for R/R B-NHL

NCT03196830 ↗

NaSingle-groupOpen-labelTreatment

Summary

This study is a single arm study to investigate the efficacy and safety of CAR-T targeted CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients. Ten patients will recruieted, admitted in hospital for 1 month for the CAR-T treatment and follow-up for at least 2 years.

Timeline

Start
2017-06-01
Primary completion
2024-01-31
Completion
2024-01-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CAR-T Cell therapy — —

Indications